DSIP or Emideltide: Why FDA Is Reviewing the “Sleep Peptide”

DSIP or Emideltide: Why FDA Is Reviewing the "Sleep Peptide"

By the Generic Peptides Team

Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal advice. Emideltide, also known as DSIP, is not approved by the FDA for insomnia, narcolepsy, opioid withdrawal, or any other medical use.

Few peptide names make a stronger promise than delta sleep-inducing peptide.

Usually shortened to DSIP, the name suggests a substance that switches on the deep, slow-wave stage of sleep. That simple story has followed the peptide since the 1970s. It has also proved difficult to confirm.

On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee, or PCAC, will review emideltide free base and emideltide acetate for possible inclusion on the 503A Bulks List.

FDA identifies emideltide as the same substance commonly called DSIP. The three proposed uses are chronic insomnia, narcolepsy, and opioid withdrawal.

Those uses were submitted through the compounding nomination process. They are not FDA findings that emideltide works for any of the three conditions.

For the full two-day agenda, see our guide to the July 2026 FDA peptide meeting.

DSIP and Emideltide Are Two Names for the Same Peptide

DSIP is the historical and widely recognized name. Emideltide is its International Nonproprietary Name, the standardized generic name used for medicinal substances.

FDA's substance database lists the names together and gives the sequence:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

This nine-amino-acid sequence is often written as WAGGDASGE.

The peptide was first isolated from blood collected from rabbits during experimentally induced sleep. Early experiments linked it with spindle and delta-wave activity on the electroencephalogram, or EEG. Delta waves are strongly associated with deep non-REM sleep, which explains the name.

The name turned out to be more definitive than the biology.

Researchers have spent decades debating where DSIP is produced, whether it has a specific receptor, whether it belongs to a larger precursor molecule, and how directly it controls sleep. A 2006 review called it a "still unresolved riddle."

That uncertainty matters. A peptide can produce an interesting EEG effect without functioning as the body's master sleep signal or becoming a reliable insomnia treatment.

Why Are Three Very Different Conditions Under Review?

Chronic insomnia, narcolepsy, and opioid withdrawal are not three versions of the same disorder.

Chronic insomnia involves persistent difficulty falling asleep, remaining asleep, or obtaining restorative sleep. Narcolepsy disrupts the control of sleep and wakefulness, often causing severe daytime sleepiness and sudden sleep attacks. Opioid withdrawal is a physiological response to stopping or reducing opioids after dependence has developed.

DSIP entered all three conversations because early researchers did not view it as a conventional sedative. They proposed that it might regulate disturbed sleep, stress responses, and interactions with endogenous opioid systems.

This produced a broad hypothesis: DSIP might help normalize a disrupted state rather than simply make a person sleepy.

That idea is scientifically interesting, but it also makes claims difficult to test. "Normalization" can mean different outcomes in different disorders. A useful insomnia treatment should improve sleep and daytime function. A narcolepsy treatment must reduce inappropriate daytime sleepiness without worsening nighttime sleep. An opioid-withdrawal treatment must control a complex and potentially serious syndrome safely.

Each indication therefore needs its own clinical evidence.

What the Insomnia Studies Actually Found

Unlike KPV, MOTS-c, and the TB-500 fragment, DSIP has been administered to people in published studies.

Most of that research is old and small.

An early 1981 experiment administered synthetic DSIP to six healthy volunteers and examined immediate and delayed effects on sleep. During the 1980s, several small studies then evaluated injections in people with disturbed sleep or insomnia.

One open study involved seven patients with severe insomnia who received a series of ten injections. Other reports described changes in sleep latency, sleep efficiency, nighttime awakenings, or slow-wave sleep.

Some of those results appeared encouraging. They helped establish DSIP's reputation as a sleep-regulating peptide.

Later controlled work was less convincing.

A 1992 double-blind study enrolled 16 people with chronic insomnia. DSIP was associated with higher sleep efficiency and shorter sleep latency on some objective measurements. The authors found that the statistically significant effects were weak, however, and could partly reflect an incidental change in the placebo group. They concluded that short-term DSIP treatment was unlikely to provide major therapeutic benefit for chronic insomnia.

This is the central insomnia problem: the literature contains positive signals, but they are inconsistent and come from small studies conducted decades ago.

The evidence does not resemble a modern insomnia-development program with:

• clearly defined diagnostic criteria;
• adequately powered randomized trials;
• consistent formulation and route;
• validated sleep and daytime-function outcomes;
• systematic adverse-event monitoring;
• longer follow-up;
• independent replication.

Why Narcolepsy Appears on the List

The narcolepsy nomination may initially sound backward. Why would a "sleep-inducing" peptide be considered for a disorder already associated with uncontrollable daytime sleep?

Narcolepsy is not simply too much sleep. It is unstable regulation of the sleep-wake cycle. People may experience severe daytime sleepiness while also having fragmented nighttime sleep.

The direct treatment evidence for DSIP is extremely narrow.

A 1984 report described repeated DSIP injections in one 35-year-old man with narcolepsy. The paper reported fewer sleep attacks and improvements in daytime alertness, activity, and performance.

One patient can produce a useful hypothesis. A single case cannot establish effectiveness, identify uncommon adverse effects, or show that the result would apply to the wider narcolepsy population.

Later research measured DSIP-like immunoreactivity in people with narcolepsy and other sleep disorders. Those biomarker studies examined naturally occurring DSIP-like material. They were not treatment trials of emideltide.

Modern narcolepsy is also understood through mechanisms involving orexin, also called hypocretin, particularly in narcolepsy type 1. The old DSIP case report predates much of that scientific framework.

The July review will therefore need to distinguish historical interest from clinically persuasive evidence.

How Opioid Withdrawal Entered the Story

Sleep disturbance, anxiety, autonomic symptoms, gastrointestinal symptoms, pain, and severe discomfort are common during opioid withdrawal. Researchers proposed that DSIP might influence both sleep and endogenous opioid-related systems.

In 1983, an uncontrolled report described intravenous DSIP as the sole treatment in 67 people presenting with withdrawal symptoms related to alcohol or opioids. Only 49 were considered evaluable. The authors reported improvement in 48 of those 49 patients, including 26 of 27 people with opioid dependence.

Those numbers sound dramatic. The study design makes them difficult to interpret.

There was no modern randomized comparison, the patient population included two different types of withdrawal, and only part of the enrolled group was included in the evaluable analysis. Withdrawal symptoms can also change rapidly with time, setting, supportive care, prior substance exposure, and other treatment.

A related 1984 publication reported results in people withdrawing from alcohol or opioids. In 1998, another paper described an open clinical trial of DSIP during opioid detoxification.

The problem is not that these reports never existed. The problem is that they were not followed by a convincing, replicated development program.

Opioid withdrawal requires medical assessment because dehydration, relapse, reduced tolerance, co-occurring illness, pregnancy, polysubstance use, and overdose risk can change the danger considerably. Historical DSIP reports should not be read as a substitute for evidence-based withdrawal management or treatment for opioid use disorder.

Why the Age of the Evidence Matters

An old study is not automatically a bad study. Some medical findings remain valid for generations.

Age matters here because the DSIP record did not mature in the way expected for a drug candidate.

The main human reports are separated by different designs, small samples, inconsistent endpoints, and limited safety documentation. Many were produced by a relatively small research community. Several appeared together in a 1984 issue of European Neurology devoted heavily to DSIP-related work.

Since then:

• sleep-disorder definitions have changed;
• polysomnography and outcome standards have improved;
• narcolepsy biology has advanced;
• opioid-withdrawal treatment has developed substantially;
• expectations for randomized trials and safety reporting have become more rigorous.

A striking result from an open study in the 1980s cannot carry the same evidentiary weight as a modern, independently replicated randomized trial.

What FDA Says About Safety

FDA's current safety summary does not say that no person has ever received DSIP. Published human studies show otherwise.

The agency uses narrower language: it says it has not identified safety-related information regarding emideltide for the proposed route of administration.

FDA also identifies:

• potential immunogenicity risk for certain routes;
• peptide-related impurities;
• complexity in characterizing the active pharmaceutical ingredient.

This distinction is important. Historical administration does not necessarily answer the safety question for the exact free-base or acetate substance, proposed formulation, manufacturing process, concentration, and route now under review.

Older publications often provide less complete adverse-event reporting than regulators expect today. They may also use preparations that cannot be shown to match a currently nominated bulk ingredient.

FDA says it lacks enough information to know whether emideltide would cause harm when administered through the proposed route. That is a conclusion about insufficient safety information, not proof that the peptide is dangerous.

What Happened to Category 2?

Emideltide previously appeared in Category 2 of FDA's interim 503A policy. That category included nominated substances for which the agency had identified potentially significant safety concerns.

By April 22, 2026, FDA had moved emideltide from the active Category 2 table to its separate table of substances whose previous nominations had been withdrawn. Separately, FDA scheduled emideltide free base and emideltide acetate for PCAC review.

The change was procedural. It did not erase FDA's safety questions or place either form on the 503A Bulks List.

PCAC will now review both forms through a public process. Its recommendation will inform FDA but will not be legally binding.

What PCAC Will Have to Untangle

FDA generally evaluates four areas for the 503A Bulks List:

1. Physical and chemical characterization.
2. Safety in compounded drug products.
3. Evidence of effectiveness.
4. Historical use in compounding.

For emideltide, the committee will face an unusual record: more human exposure than several other peptides on the agenda, but much of it old, fragmented, and difficult to connect to a modern compounded product.

The committee may need to ask:

• Which exact route and formulation were nominated?
• Did older studies use the free base, an acetate form, or another preparation?
• Can the identity and purity of historical study material be verified?
• Are the insomnia findings consistent enough to support chronic use?
• Can one narcolepsy case carry any meaningful weight?
• Are uncontrolled withdrawal reports reliable enough for a high-risk indication?
• Is there a documented history of compounding with a consistent substance?

The three indications should not be treated as one general claim about "better sleep." A recommendation could reasonably differ by use, route, or chemical form, depending on the final voting questions.

What the July Recommendation Could Change

FDA will publish the exact voting questions with the meeting materials. Depending on their wording, PCAC may consider emideltide free base and emideltide acetate separately and recommend inclusion or exclusion from the 503A Bulks List.

A favorable recommendation would not approve emideltide as a drug. It would not establish that DSIP treats insomnia, narcolepsy, or opioid withdrawal. FDA would still need to consider the committee's advice and complete notice-and-comment rulemaking.

That process can take months or years.

If FDA eventually includes an emideltide form, drugs compounded from that bulk substance could qualify for section 503A exemptions when every other statutory requirement is met.

If FDA ultimately decides against inclusion, products compounded from the substance would not qualify for those exemptions under section 503A.

What to Watch on July 24

FDA plans to publish briefing documents no later than two business days before the meeting. The most important details may be:

• the proposed routes and dosage forms;
• whether FDA can match historical DSIP preparations to the nominated substances;
• how the agency interprets the weak 1992 insomnia result;
• whether the narcolepsy evidence extends beyond one case;
• how FDA evaluates the old withdrawal reports and the 1998 open trial;
• what safety information exists for repeated administration;
• whether the three uses receive separate voting questions.

Public comments may be submitted to docket FDA-2025-N-6895 until 11:59 p.m. Eastern Time on July 22, 2026. Comments received by July 9 will be provided to the committee before the meeting.

The July 24 session is scheduled for 8:00 a.m. to 3:50 p.m. Eastern Time, with an online viewing option.

The Bottom Line

DSIP is not a modern peptide with no human history. People received it in sleep and withdrawal studies decades ago.

That history is precisely why the July review is interesting. The committee must decide how much weight to give small, old, inconsistent studies when the nominated uses include three complex conditions and FDA says route-specific safety information is missing.

Emideltide may have earned the nickname "sleep peptide." The evidence has not earned an equally simple conclusion.

---